Member Info for Fadec92

RMM there’s is an upward trend on no volume, any sort of buying and this will go north definitely!

Recent Publication and full list of inhibitors there with srra chk1!

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

“PDAC (Pancreatic ductal adenocarcinoma) is projected to be the second most common cause of cancer-related death by 2030”

“But potentially more promising might be the combination of a PARP inhibitor with an ATR inhibitor in ATM-deficient PDAC—essentially exploiting a new node of synthetic lethality in the DDR pathway. Similarly, there is a mechanistic reason to explore the role of CHK1 inhibition in ATM-deficient tumors. In both cases, understanding the need for inducing DNA damage with DNA-damaging chemotherapy will be critical as well. There are several ongoing clinical trials as discussed above, but clinical trials in PDAC in which there is such a high unmet need, and where ATM deficiency is common, would be ideal.”

https://mct.aacrjournals.org/content/18/11/1899

PDF Version :-

https://mct.aacrjournals.org/content/molcanther/18/11/1899.full.pdf

I would defo do that for £58k!

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

https://www.cell.com/action/showPdf?pii=S1535-6108%2808%2900437-6

Another way is to use your jacket as defense to restrict the knife arm, hopefully restricting the attacking movements of the opposition, don’t get close without a weapon and a plan or a group of people without a similar ethos!

Its a slow process two lots of Toxicology study’s (Short and Long) and a reliable manufacturing process there’s a clear difference between the 2 molecules development but being done with value in mind, the only dynamic element missing would be the PR, would extra money help the process maybe It would, it would certainly help the sp knowing that funding is not required!

They have the chosen corporate skill sets with two value for money experience in the recent directors, what could they do to push on quicker there is an element of company growth they are responsible in advising on what sort of growth (sp or a development partner), they could employ a good PR company to tweet the bits of the Final Report would cost money offcourse would people want that here, if so then it’s definitely worth asking for that service as there is no coverage only on RNS’s days, Parker’s tweets are not good enough and is not reaching the right audience and I’m sure a cost effective company can be found!

Credit due thats an honest and professional annual report, got to to say!

Looks like everyone state side happy to get the funding completed with the investment funds, board members in place and a bit of volume to pull it off the bottom, it’s a bit fake as they did say what was happening corporate wise a while ago, perhaps cementing the fact has made an impact!

I’m with you there Potnak, what’s another 6m after 4years! :/)

Chancer 1,693,748 jumping on then selling taking a £203 loss! Good trading day!

Original CHK1 paper John Reader in 2012!

https://pubs.acs.org/doi/pdf/10.1021/jm3012933

Basically PetroTeq are now proving production at their purpose built plant for the extraction of heavy oil from oil sands and are using their proprietary technology that doesn't use any water to extract ie like traditional extraction methods!

They use a patented solvent that can be 99% removed from the process, but also extract 99% of the oil from the oil sand and leave near enough clean sand, it’s like it cleans up the area!

The facility is near Vernal Utah where most of the oil sands in the U.S resides, something like 16billion barrels of oil sands there, they have a CPR of proven reserves at Asphalt Ridge of 90M barrels recovery on this property alone and they have a bigger resource at PR Springs!

There is no Decline curves like conventional/unconventional oil and gas, so you keep on producing high quality heavy oil it’s recently been confirmed to contain low sulfur so is going to be in demand at the oil refineries as the new shipping low sulfur laws for marine shipping kicks in in Jan 2020!

The break even per price barrel is lower than any oil and gas project I’ve seen in the U.S better than Permian Basin/Scoop and Stack in Oklahoma probably around $25per barrel!

The share price is at the bottom and is probably ready to move after a consolidation around this area!

Petroteq Announces Completion of Automation, Strategic Account Payment Structure With Valkor Oil and Gas and Appoints New Advisory Board Member

“Petroteq Energy Inc, an oil sands mining and production company having a proprietary technology that extracts hydrocarbons from oil sands without the use of water, is pleased to announce the completion of facility automation, a strategic account payment structure with Valkor Oil and Gas (“Valkor”) and the addition of Dr. Mark Rollins to its advisory board.

The Company has completed the automation of the front end processes for sand separation, oil quality control and centrifugal agitation. The Company believes that with the engineering and technical assistance from Valkor and Alfa Laval, its production of crude oil and potential reduction in operating, maintenance and labor costs will now be achieved. This marks a very important milestone in becoming an oil company focused on the development and implementation of a proprietary, environmentally clean technology for heavy oil extraction“

TSXV:PQE
OTC:PQEFF

https://content.equisolve.net/_e4acb3d204e67146c89551aeff407a7f/petroteq/news/2019-11-20_Petroteq_Announces_Completion_of_Automation_338.pdf

Keep the faith Obelix, hope that helps!

It’s unbelievable with the success of Keytruda (PD-L1) the UK lags behind EU and US, but have the top institutions where the guy in the article had the trial at the Royal Marsden the same place as we know where SRA737 is in trial!

“A test for the presence of immune marker PD-L1 in the tumour means doctors can work this out.
Prof Harrington says approximately 85% of people with advanced or relapsed head and neck cancer would be eligible for pembrolizumab - around 1,300 patients a year.“

Did he say why Thoth, probably srra!

I think we would be aggrieved with a 50m buyout then that dosnt leave a lot for clinical trials for the new additions, they haven’t got enough to progress assets they have let alone more!

Chk1 was designed to work in combination, it stops certain genetic cancer mutations reconnecting the DNA strands by homologous recombination, mis match repair Gemtitabine kills it and switches the cancer into RS replication stress and looks to ATM, ATR, WEE1 and CHK1 to be able to repair,

It inhibits the repair!

There’s far far worse than Utah on other sites, don’t know if you can take that as a positive Utah, not sticking up for you personally, I’ve been overly excited sometimes to reach nowhere and it’s not all plain sailing so until the time is right the doubters are in a better position than the positive people, so down the company to be able to perform, which we all can agree on is happening in the lab!

Can’t rush it everything must be just right, Pfizer was the other one with Tyk2 and JAK1 in psoriasis but they consentrated with their JAk1 (Abrocitinib)in the same indication I haven’t heard they dropped it but consentrated with the JAK1!
Pfizer PF-841 their Tyk2/Jak1

https://server.aad.org/eposters/Submissions/getFile.aspx?id=4546&type=sub

Just Abrocitinib

https://s21.q4cdn.com/317678438/files/doc_financials/2019/q3/Q3-2019-Earnings-Charts-FINAL.pdf

https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_second_pivotal_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis

Structure Activity Relationship (SAR) that what the name stands for John has worked hard in this and have had some bright minds around with the Oxazole tyrosine kinase inhibitors structures!